一覧に戻る

タイトル
  • Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors for Cardiovascular and Renal Points of View
作成者
    • Bando, Hiroshi
権利情報
  • © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
主題
  • Other Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
  • Other Canagliflozin Cardio-Vascular Assessment Study (CANVAS)
  • Other Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)
  • Other Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58
  • Other The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) Study
内容注記
  • Other Diabetes has been a major medical and health problem worldwide. Adequate glycemic control has shown a clinically beneficial effect for long-term prognosis, with recent anti-diabetic agents. There are some mega studies concerning Sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are i) Canagliflozin cardioVascular Assessment Study (CANVAS), ii) Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), iii) Dapagliflozin Effect on CardiovascuLAR Events (DECLARE) -TIMI 58, iv) Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study. Current topics of SGLT2 inhibitors for cardiovascular and renal points of view were described.
出版者 Asploro
日付
    Issued2020-01-30
言語
  • eng
資源タイプ journal article
出版タイプ VoR
資源識別子 URI http://repo.lib.tokushima-u.ac.jp/114800
関連
  • isIdenticalTo DOI https://doi.org/10.36502/2020/droa.6156
収録誌情報
  • Diabetes Research : Open Access
  • 巻2 号S1 開始ページ9 終了ページ13
ファイル
コンテンツ更新日時 2023-06-26